Top News Stories
News
GlaxoSmithKline & other drugmakers delist FDA patents, after FTC 'Big Pharma' scrutiny
By Alan GoforthAfter the Federal Trade Commission sent warning letters to 10 drugmakers over 100 "improper" patents, 3 chose to delist their patents from the FDA's registry, potentially accelerating the approval of generic versions.










